A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
22
Participants
Timeline
Start Date
May 31, 2022
Primary Completion Date
May 31, 2024
Study Completion Date
January 31, 2026
Conditions
Patients With Advanced Solid Tumors
Interventions
DRUG
ICP-189
Administered orally
Trial Locations (1)
200433
Shanghai Pulmonary Hospital, Shanghai
All Listed Sponsors
lead
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY
NCT05370755 - A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter